Arcutis Biotherapeutics Ownership
| ARQT Stock | USD 13.24 0.43 3.15% |
Shares in Circulation | First Issued 2018-12-31 | Previous Quarter 123.5 M | Current Value 124.3 M | Avarage Shares Outstanding 54 M | Quarterly Volatility 31.2 M |
Arcutis |
Arcutis Stock Ownership Analysis
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.67. Arcutis Biotherapeutics had not issued any dividends in recent years. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 147 people. For more info on Arcutis Biotherapeutics please contact Todd MA at 805 418 5006 or go to https://www.arcutis.com.Besides selling stocks to institutional investors, Arcutis Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Arcutis Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Arcutis Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Arcutis Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
Arcutis Biotherapeutics Insider Trades History
Only 1.93% of Arcutis Biotherapeutics are currently held by insiders. Unlike Arcutis Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Arcutis Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Arcutis Biotherapeutics' insider trades
Arcutis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arcutis Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcutis Biotherapeutics backward and forwards among themselves. Arcutis Biotherapeutics' institutional investor refers to the entity that pools money to purchase Arcutis Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.5 M | Ensign Peak Advisors Inc | 2024-09-30 | 2.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 2.3 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-09-30 | 2.1 M | Stempoint Capital Lp | 2024-09-30 | 1.8 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.7 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.6 M | Goldman Sachs Group Inc | 2024-09-30 | 1.6 M | J. Goldman & Co Lp | 2024-09-30 | 1.5 M | Jennison Associates Llc | 2024-09-30 | 11.7 M | Rubric Capital Management Lp | 2024-09-30 | 11 M |
Arcutis Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcutis Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcutis Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcutis Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arcutis Biotherapeutics Outstanding Bonds
Arcutis Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arcutis Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arcutis bonds can be classified according to their maturity, which is the date when Arcutis Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US039653AA89 Corp BondUS039653AA89 | View | |
| Ardagh Holdings USA Corp BondUS03969AAP57 | View | |
| Ardagh Holdings USA Corp BondUS03969AAN00 | View | |
| Ardagh Packaging Finance Corp BondUS03969AAR14 | View | |
| US03969YAA64 Corp BondUS03969YAA64 | View | |
| US03969YAB48 Corp BondUS03969YAB48 | View |
Arcutis Biotherapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 24th of July 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.